GlobeNewswire

ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026
04/11/2026
Three iadademstat abstracts have been accepted for presentation Updated data from the ongoing Phase Ib ALICE-2 trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a [...]
J-Star Holding Co., Ltd. Provides Update on Capital Structure Authorization and Strategic Execution Timeline
04/11/2026
TAICHUNG, Taiwan, Nov. 04, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), an innovator in advanced composite manufacturing, today provided a clarification regarding the [...]
Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
04/11/2026
First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/ [...]
Ichnos Glenmark Innovation (IGI) to Present Updated Clinical Data for ISB 2001 (ABBV-2001) in Relapsed/Refractory Multiple Myeloma at 68th ASH Annual Meeting
04/11/2026
ISB 2001 (ABBV-2001) is an investigational first- and only-in-class CD38 × BCMA × CD3 trispecific T-cell engager Updated data from the Phase 1 TRIgnite-1 study include longer follow-up from the dose-escalation phase and [...]
Biodesix to Participate in Upcoming Investor Conferences
04/11/2026
LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present at two upcoming [...]
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
04/11/2026
Clinical data demonstrate target engagement and support the potential for BH-30236 to address therapeutic resistance in relapsed/refractory AML and HR-MDS SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- BlossomHill [...]
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
04/11/2026
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label long-term safety trial expected in 4Q [...]
Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
04/11/2026
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to [...]
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
04/11/2026
Conference Call and Webcast Today at 8:30 a.m. ET Received Provisional Approval and Priority Designation for OCU400 in The Bahamas Executed agreement with local partner Global Alliance for Regenerative Medicine (GARM) [...]
Verano Expands Florida Retail Footprint to 87 Locations with Grand Opening of MÜV Fernandina Beach, the Company’s 164th Dispensary Nationwide
04/11/2026
Situated on the scenic Amelia Island in Florida’s Nassau County, MÜV Fernandina Beach is located at 1940 S 8 th Street, a busy thoroughfare that averages a daily traffic count of 20,100 vehicles daily 1 MÜV Fernandina [...]
Biora Therapeutics Receives Approval for First-in-Human Trial of BioJet™ Oral Biologic Delivery Capsule
04/11/2026
Company remains on track to initiate clinical study evaluating oral, needle-free delivery of adalimumab in December 2026 with data expected in early 2027 SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biora Therapeutics, [...]
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
04/11/2026
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor $ [...]
BioCryst Reports Third Quarter 2026 Financial Results
04/11/2026
— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue [...]
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
04/11/2026
In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. The Company’s lead [...]
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
04/11/2026
CORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
04/11/2026
BERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced [...]
Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2026
04/11/2026
BANNOCKBURN, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
Repligen Corporation to Present at Jefferies Global Healthcare Conference
04/11/2026
WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and [...]
Sironax Announces Two Abstracts on NAMPT Activator SIR4156 Selected for Presentation at ObesityWeek 2026
04/11/2026
Obesity Society annual meeting, November 14-17 Gaylord National Resort & Convention Center, National Harbor, MD WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum